We read with great interest the study of Mergental et al.(1)reporting the 5-year outcomes of the VITTAL trial(2,3).VITTAL was a prospective,non-randomized,single-arm trial that tested end-ischemic oxygenated normother...We read with great interest the study of Mergental et al.(1)reporting the 5-year outcomes of the VITTAL trial(2,3).VITTAL was a prospective,non-randomized,single-arm trial that tested end-ischemic oxygenated normothermic machine perfusion(NMP)with a“back-to-base”strategy to evaluate,and potentially transplant,liver grafts declined by all liver transplantation(LT)centers in the United Kingdom.For a liver to be considered viable,it had to metabolize perfusate lactate to a concentration of≤2.5 mmol/L within four hours from the start of perfusion,and meet at least two of the following criteria:bile production without a defined quantity;maintenance of perfusate pH above 7.3;glucose consumption in the perfusate;maintenance of stable arterial and portal flow above 150 and 500 mL/min,respectively;maintenance of graft suppleness and homogeneous perfusion(4).Thirty-one discarded human donor livers underwent viability testing by using end-ischemic NMP,of which 22(71%)livers were subsequently transplanted.The primary outcome of the trial was graft survival rate at 90 days and it was 100%.展开更多
We read with great interest the article by van Rijn et al.published in March 2021,in The New England Journal of Medicine(1).In this multicenter,randomized controlled trial,the authors investigated the efficacy of dual...We read with great interest the article by van Rijn et al.published in March 2021,in The New England Journal of Medicine(1).In this multicenter,randomized controlled trial,the authors investigated the efficacy of dual hypothermic oxygenated perfusion(D-HOPE)versus static cold storage(SCS)in grafts from donors after cardiac death(DCD)to decrease the rate of non-anastomotic biliary stenosis(NAS)within the first 6 post-transplant months.展开更多
文摘We read with great interest the study of Mergental et al.(1)reporting the 5-year outcomes of the VITTAL trial(2,3).VITTAL was a prospective,non-randomized,single-arm trial that tested end-ischemic oxygenated normothermic machine perfusion(NMP)with a“back-to-base”strategy to evaluate,and potentially transplant,liver grafts declined by all liver transplantation(LT)centers in the United Kingdom.For a liver to be considered viable,it had to metabolize perfusate lactate to a concentration of≤2.5 mmol/L within four hours from the start of perfusion,and meet at least two of the following criteria:bile production without a defined quantity;maintenance of perfusate pH above 7.3;glucose consumption in the perfusate;maintenance of stable arterial and portal flow above 150 and 500 mL/min,respectively;maintenance of graft suppleness and homogeneous perfusion(4).Thirty-one discarded human donor livers underwent viability testing by using end-ischemic NMP,of which 22(71%)livers were subsequently transplanted.The primary outcome of the trial was graft survival rate at 90 days and it was 100%.
文摘We read with great interest the article by van Rijn et al.published in March 2021,in The New England Journal of Medicine(1).In this multicenter,randomized controlled trial,the authors investigated the efficacy of dual hypothermic oxygenated perfusion(D-HOPE)versus static cold storage(SCS)in grafts from donors after cardiac death(DCD)to decrease the rate of non-anastomotic biliary stenosis(NAS)within the first 6 post-transplant months.
